To include your compound in the COVID-19 Resource Center, submit it here.

Alder receives rights to eptinezumab IP from Teva

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) gained $2.25 (17%) to $15.20 on a newsy Monday during which Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) granted the company rights to IP related to

Read the full 304 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE